- Home
- ACIC vs LRMR Comparison
ACIC vs LRMR Comparison
Compare ACIC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | LRMR |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.5M | 455.8M |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACIC | LRMR |
|---|---|---|
| Price | $10.46 | $3.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 269.4K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 39.61 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | $1,816.14 |
| P/E Ratio | $26.77 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.80 | $2.26 |
| 52 Week High | $13.06 | $6.42 |
Technical Indicators
Market Signals| Indicator | ACIC | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 48.71 |
| Support Level | $10.31 | $3.10 |
| Resistance Level | $11.39 | $3.74 |
| Average True Range (ATR) | 0.27 | 0.20 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 55.83 | 82.81 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.